August 14, 2025

Patient characteristics, healthcare resource utilization and costs across treatment lines in diffuse large B-cell lymphoma - a German claims data study.

View Full Paper

Ask AI

Bookmark

High healthcare costs were observed for DLBCL patients, with average hospitalization costs of €12,777 in first-line treatment and €17,408 in third-line treatment.
Over 49% of 2L patients and 21% of 3L patients experienced disease progression, coupled with significant clinical complications.
The retrospective cohort study utilized German claims data from AOK PLUS to evaluate patients diagnosed with DLBCL from 2012 to 2022.
These findings highlight the complexity of treatment in DLBCL, underscoring the need for more effective and manageable treatment options.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Retrospective cohort analysis shows high healthcare costs and clinical complications in diffuse large B-cell lymphoma patients across treatment lines, indicating urgent need for better therapies.

Cite This Study

Oppelt et al. (2025) studied this question.

synapsesocial.com/papers/689fc957e46e096235ce1aef https://doi.org/10.57264/cer-2024-0218

View Full Paper

Ask AI

Bookmark

Implication

Retrospective cohort analysis shows high healthcare costs and clinical complications in diffuse large B-cell lymphoma patients across treatment lines, indicating urgent need for better therapies.

Patient characteristics, healthcare resource utilization and costs across treatment lines in diffuse large B-cell lymphoma - a German claims data study.

Key Points

Discussion

Implication

Cite This Study

Patient characteristics, healthcare resource utilization and costs across treatment lines in diffuse large B-cell lymphoma - a German claims data study.

Key Points

Discussion

Implication

Cite This Study